Moreover, both the CPT1 inhibitor perhexiline and an anti-leptin antibody are able to mitigate tumor growth by upregulating cytokine release by CD8+ T cells, indicating that targeting the leptin-PD-1-STAT3-FAO pathway represents a new direction in treating breast cancer [70, 95]. Here, CD8A is linked to neoplasm.